Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($1.13), $0.06 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $57 million versus the consensus estimate of $53.71 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.